Growth Investors: Industry Analysts Just Upgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue Forecasts By 33%

Celebrations may be in order for Assembly Biosciences, Inc. (NASDAQ:ASMB) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects.

Our free stock report includes 4 warning signs investors should be aware of before investing in Assembly Biosciences. Read for free now.

Following the upgrade, the latest consensus from Assembly Biosciences' twin analysts is for revenues of US$41m in 2025, which would reflect a major 28% improvement in sales compared to the last 12 months. Before the latest update, the analysts were foreseeing US$31m of revenue in 2025. It looks like there's been a clear increase in optimism around Assembly Biosciences, given the considerable lift to revenue forecasts.

View our latest analysis for Assembly Biosciences

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. One thing stands out from these estimates, which is that Assembly Biosciences is forecast to grow faster in the future than it has in the past, with revenues expected to display 39% annualised growth until the end of 2025. If achieved, this would be a much better result than the 32% annual decline over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 17% annually. Not only are Assembly Biosciences' revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.

The Bottom Line

The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. They're also forecasting more rapid revenue growth than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Assembly Biosciences.

These earnings upgrades look like a sterling endorsement, but before diving in - you should know that we've spotted 4 potential warning signs with Assembly Biosciences, including major dilution from new stock issuance in the past year. For more information, you can click through to our platform to learn more about this and the 2 other warning signs we've identified .

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.